Northeast Pharmaceutical Group Co., Ltd.

SZSE:000597 Rapport sur les actions

Capitalisation boursière : CN¥7.2b

Northeast Pharmaceutical Group Résultats passés

Passé contrôle des critères 1/6

Northeast Pharmaceutical Group has been growing earnings at an average annual rate of 35.5%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 1.5% per year. Northeast Pharmaceutical Group's return on equity is 6.8%, and it has net margins of 4.3%.

Informations clés

35.5%

Taux de croissance des bénéfices

33.8%

Taux de croissance du BPA

Pharmaceuticals Croissance de l'industrie10.9%
Taux de croissance des recettes1.5%
Rendement des fonds propres6.8%
Marge nette4.3%
Dernière mise à jour des bénéfices30 Sep 2024

Mises à jour récentes des performances passées

Northeast Pharmaceutical Group's (SZSE:000597) Weak Earnings May Only Reveal A Part Of The Whole Picture

Oct 30
Northeast Pharmaceutical Group's (SZSE:000597) Weak Earnings May Only Reveal A Part Of The Whole Picture

Recent updates

Northeast Pharmaceutical Group's (SZSE:000597) Weak Earnings May Only Reveal A Part Of The Whole Picture

Oct 30
Northeast Pharmaceutical Group's (SZSE:000597) Weak Earnings May Only Reveal A Part Of The Whole Picture

It's A Story Of Risk Vs Reward With Northeast Pharmaceutical Group Co., Ltd. (SZSE:000597)

Aug 07
It's A Story Of Risk Vs Reward With Northeast Pharmaceutical Group Co., Ltd. (SZSE:000597)

These 4 Measures Indicate That Northeast Pharmaceutical Group (SZSE:000597) Is Using Debt Safely

May 25
These 4 Measures Indicate That Northeast Pharmaceutical Group (SZSE:000597) Is Using Debt Safely

Northeast Pharmaceutical Group (SZSE:000597) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Apr 05
Northeast Pharmaceutical Group (SZSE:000597) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Ventilation des recettes et des dépenses

Comment Northeast Pharmaceutical Group gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.


Historique des gains et des recettes

SZSE:000597 Recettes, dépenses et bénéfices (CNY Millions )
DateRecettesLes revenusDépenses G+ADépenses de R&D
30 Sep 247,9733472,056108
30 Jun 247,9053802,066108
31 Mar 247,8293462,270101
31 Dec 238,2433582,57397
30 Sep 238,6434422,839146
30 Jun 238,8953733,031146
31 Mar 238,8103522,913152
01 Jan 238,8093502,789160
30 Sep 228,6092022,727106
30 Jun 228,5551512,752102
31 Mar 228,4781292,77693
31 Dec 218,145992,71183
30 Sep 218,003372,61362
30 Jun 217,671142,53061
31 Mar 217,465712,45869
31 Dec 207,384122,45374
30 Sep 207,659-12,75176
30 Jun 207,8331132,78474
31 Mar 208,026972,90173
31 Dec 198,2201743,01464
30 Sep 197,8982142,880137
30 Jun 197,8281982,823154
31 Mar 197,6222002,724148
31 Dec 187,4671952,581145
30 Sep 187,1021962,44373
30 Jun 186,6591962,21472
31 Mar 186,2041601,98762
31 Dec 175,6761191,74058
30 Sep 175,271981,47026
30 Jun 175,176601,4160
31 Mar 175,016391,3180
31 Dec 164,814241,2360
30 Sep 164,581-1561,2040
30 Jun 164,122-2951,2040
31 Mar 164,031-3581,2230
31 Dec 153,834-3841,1530
30 Sep 154,006-1941,0780
30 Jun 154,092-771,0090
31 Mar 154,223-81,0390
31 Dec 144,333871,0770
30 Sep 144,260-271,2240
30 Jun 144,199-561,2260
31 Mar 144,022-771,1780
31 Dec 133,871-1671,1300

Des revenus de qualité: 000597 has a large one-off gain of CN¥206.2M impacting its last 12 months of financial results to 30th September, 2024.

Augmentation de la marge bénéficiaire: 000597's current net profit margins (4.3%) are lower than last year (5.1%).


Analyse des flux de trésorerie disponibles par rapport aux bénéfices


Analyse de la croissance passée des bénéfices

Tendance des revenus: 000597's earnings have grown significantly by 35.5% per year over the past 5 years.

Accélération de la croissance: 000597's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Bénéfices par rapport au secteur d'activité: 000597 had negative earnings growth (-21.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-1.2%).


Rendement des fonds propres

ROE élevé: 000597's Return on Equity (6.8%) is considered low.


Rendement des actifs


Rendement des capitaux employés


Découvrir des entreprises performantes dans le passé